The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | Barriers to progressing CLL treatment in Taiwan: treatment access and biomarkers
Shang-Ju Wu, MD, PhD, National Taiwan University Hospital, Taipei, Taiwan, discusses the barriers to progressing chronic lymphocytic leukemia (CLL) treatment in Taiwan, highlighting the limited availability of novel agents and the financial burden on patients due to out-of-pocket expenses. Additionally, biomarker testing is not routinely performed in most hospitals, limiting treatment options and decisions for the small patient population. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
